

Akrit Sodhi, M.D., Ph.D.  
Assistant Professor of Ophthalmology  
Retina Division  
Smith Building, Office 4039  
Wilmer Eye Institute  
Johns Hopkins Medical Institutions  
400 North Broadway  
Baltimore, MD  
21231  
  
410-614-6682 (academic office)  
410-614-4211 (administrative office)  
410-614-8577 (fax)

March 14, 2013

Lian-Sheng Ma, President and Editor-in-Chief  
World Series Journals  
Baishideng Publishing Group Co., Limited  
Room 903, Building D,  
Ocean International Center,  
No.62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-5908-0036  
Fax: +86-10-8538-1893  
E-mail: [l.s.ma@wjgnet.com](mailto:l.s.ma@wjgnet.com)

RE: ESPS Manuscript NO: 1685

Dear Dr. Ma:

Thank you for your letter of February 6<sup>th</sup>, 2013 regarding our manuscript entitled “Ranibizumab in Diabetic Macular Edema,” and for giving us the opportunity to revise our paper. We were appreciative of the thorough and positive review from the reviewer and found the suggestions of the reviewer to be insightful and very helpful. Please, see below for a description of how we addressed each of the issues brought up by the reviewer. We respectfully ask that you consider this revised version of our manuscript for publication in *World Journal of Diabetes*.

**Major Points:**

**1. A section about adverse events in randomized trials should be added.**

Agree. Sections addressing this important topic were added to the text and are highlighted in yellow.

**2. The reviewer understands that numbers about cardiovascular events are low but there remains a concern about strokes as outlined in the FDA Briefing book for the 0.5 dose which should be mentioned.**

Agree. We discuss this important point in the text; this addition is also highlighted in yellow.

**3. The reviewer understands that bevacizumab will be discussed elsewhere in this review series. However, I believe that it would be helpful to discuss some comparative effectiveness data here as well.**

Agree. We added a brief section discussing the comparison of bevacizumab to ranibizumab as requested. This section is also highlighted in yellow.

**4 . A few typos: p3, 8th line from the bottom: remove ?a“ 50%; p6, second paragraph: ...that was FDA approved... (that was is there twice)**

Agree. Thank you for pointing these out. These errors were addressed.

We have also updated the text to include the most recent data from the DRCR.net and we have addressed the editorial issues pointed out in your review of the manuscript.

We feel the additions we have made to our manuscript address the issues brought up by the reviewer during the initial review. We therefore respectfully request that you consider the enclosed revised manuscript for publication in *World Journal of Diabetes*.

Thank you very much,

Sincerely,

Akrit Sodhi

A handwritten signature in black ink, appearing to read 'Akrit Sodhi', with a stylized flourish at the end.

Akrit Sodhi, M.D., Ph.D.  
Assistant Professor of Ophthalmology  
Retina Division  
Smith Research Building, Office 4039  
Wilmer Eye Institute  
Johns Hopkins Medical Institutions

**Corresponding Author:**

Akrit Sodhi  
[asodhi1@jhmi.edu](mailto:asodhi1@jhmi.edu)  
410-614-6682 (academic office)  
410-614-4211 (administrative office)  
410-614-8577 (fax)